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A

LTHOUGH RED BLOOD CELL

(RBC) transfusions are used
routinely in acutely ill patients, including those in neonatal intensive care units, the clinical
consequences of the prolonged storSee also Patient Page.
CME available online at
www.jamaarchivescme.com
and questions on p 1485.

Context Even though red blood cells (RBCs) are lifesaving in neonatal intensive care,
transfusing older RBCs may result in higher rates of organ dysfunction, nosocomial
infection, and length of hospital stay.
Objective To determine if RBCs stored for 7 days or less compared with usual standards decreased rates of major nosocomial infection and organ dysfunction in neonatal intensive care unit patients requiring at least 1 RBC transfusion.
Design, Setting, and Participants Double-blind, randomized controlled trial in
377 premature infants with birth weights less than 1250 g admitted to 6 Canadian
tertiary neonatal intensive care units between May 2006 and June 2011.
Intervention Patients were randomly assigned to receive transfusion of RBCs stored
7 days or less (n=188) vs standard-issue RBCs in accordance with standard blood bank
practice (n=189).
Main Outcome Measures The primary outcome was a composite measure of major neonatal morbidities, including necrotizing enterocolitis, retinopathy of prematurity, bronchopulmonary dysplasia, and intraventricular hemorrhage, as well as death.
The primary outcome was measured within the entire period of neonatal intensive care
unit stay up to 90 days after randomization. The rate of nosocomial infection was a
secondary outcome.
Results The mean age of transfused blood was 5.1 (SD, 2.0) days in the fresh RBC
group and 14.6 (SD, 8.3) days in the standard group. Among neonates in the fresh
RBC group, 99 (52.7%) had the primary outcome compared with 100 (52.9%) in the
standard RBC group (relative risk, 1.00; 95% CI, 0.82-1.21). The rate of clinically suspected infection in the fresh RBC group was 77.7% (n=146) compared with 77.2%
(n=146) in the standard RBC group (relative risk, 1.01; 95% CI, 0.90-1.12), and the
rate of positive cultures was 67.5% (n=127) in the fresh RBC group compared with
64.0% (n=121) in the standard RBC group (relative risk, 1.06; 95% CI, 0.91-1.22).
Conclusion In this trial, the use of fresh RBCs compared with standard blood bank
practice did not improve outcomes in premature, very low-birth-weight infants requiring a transfusion.
Trial Registration clinicaltrials.gov Identifier: NCT00326924; Current Controlled Trials
Identifier: ISRCTN65939658
JAMA. 2012;308(14):1443-1451
Published online October 8, 2012. doi:10.1001/2012.jama.11953

age of RBCs have not been firmly established. Reported adverse consequences have been attributed to the
generation of cytokines in the storage
medium. 1 Changes to RBC mem-
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koreduction given the possible interaction between length of storage and
presence of white blood cells.18
In neonatal intensive care, the dedicated donor policy provided an ideal
setting in which to evaluate the effects
of prolonged RBC storage in vulnerable patients. Therefore, our objective
in the Age of Red Blood Cells in Premature Infants (ARIPI) trial was to
evaluate whether RBCs stored for 7 days
or less decreased serious neonatal morbidity and mortality compared with
standard blood bank issue.

Figure 1. Participant Flow
1752 Neonates assessed for eligibility

1375 Excluded
362 Declined
252 Transfusion not required
236 Directed blood donations
218 Already underwent transfusion
39 Deaths
39 Transferred elsewhere
27 Mitigating circumstances
3 Lethal anomalies
199 Other reasons

377 Randomized

189 Randomized to receive standard
red blood cell transfusions
189 Received standard
transfusions as assigned

188 Randomized to receive fresh red
blood cell transfusions
174 Received fresh red blood cell
transfusions as assigned
14 Received ≥1 transfusion of
red blood cells stored >7 d

188 Completed trial
1 Had consent withdrawn for
intervention but agreed to
complete follow-up

187 Completed trial
1 Had consent withdrawn for
intervention but agreed to
complete follow-up

189 Included in primary intentionto-treat analysis

188 Included in primary intentionto-treat analysis

branes that alter deformability of RBCs
and an inability to scavenge nitric oxide and biochemical changes such as decreased levels of 2,3-diphosphoglycerate may be even more important than
the generation of cytokines because they
impair the ability of RBCs to deliver
oxygen to meet tissue needs.2,3 In vulnerable patients such as critically ill premature infants, transfusing older RBCs
may result in higher rates of organ dysfunction and morbidity because of the
deleterious oxygen deficits or the
proinflammatory effects of bioactive
materials that accumulate during RBC
storage.
In recent years, several observational studies conducted primarily in
adults have demonstrated that prolonged RBC storage is associated with
increased rates of infection, organ failure, death, and increased lengths of
stay.4-14 Unfortunately, it is extremely
difficult to disentangle cause-effect relationships in observational studies,
wherein sicker patients often receive
more RBC transfusions and, frequently, a greater number of older units.
1444
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METHODS
In 6 Canadian tertiary neonatal intensive care units, we enrolled infants in
a double-blind, randomized controlled trial comparing the clinical consequences of transfusing RBCs stored
for 7 days or less vs standard practice
between May 2006 and June 2011.19
The study was approved by the research ethics boards both at the central coordinating center and at each of
the participating sites.

Premature infants requiring multiple transfusions are routinely exposed to older RBCs because of a “dedicated” donor policy introduced in the
1980s to decrease the risk of viral transmission through transfusions of blood
from multiple donors. The dedicated
donor policy designates a specific unit
of donated RBCs for use by 1 infant exclusively over the course of his/her
transfusion needs up to the expiration
date of the unit. Despite the inherent
significant decrease in risk of viral transmission with dedicated units, by design this approach increases rates of
transfusion of older RBCs. The policy
remains a standard of practice in most
neonatal intensive care units in Canada
and the United States.15,16 In a previous study examining RBC characteristics and their impact on outcomes, we
documented that transfusion of leukoreduced RBCs was associated with a
decrease in organ injury in premature
infants17; therefore, the type of RBCs
transfused may matter. It is possible that
prolonged cell storage may have exacerbated the observed effect of nonleu-

Study Population

We assessed the eligibility of all premature infants admitted to each of the
6 participating neonatal intensive care
units who had a birth weight of less than
1250 g and required 1 or more RBC
transfusion for the treatment of anemia. We excluded premature infants
who had already received an RBC transfusion, were scheduled to undergo an
exchange transfusion or to receive a directed donation, had rare blood types
that would lead to difficulty with crossmatching, were moribund on admission to the neonatal intensive care unit,
were not expected to survive because
of a severe congenital anomaly, or
whose attending clinical team specifically requested fresh RBCs.
A representative in each infant’s
health care team approached families
to ask if they would be willing to have
a research coordinator speak to them
about the study. If yes, the coordinator described the study (risks/
benefits, voluntary participation, procedures). Families were given adequate
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time to reflect on the information and
had any questions answered. Parents or
legal guardians then provided written
informed consent. We did not approach parents or guardians of infants
when the health care team thought it
was inappropriate (eg, extreme family
crisis, child protection issues). Race/
ethnicity of the infants was not ascertained; however, research coordinators as cert aine d p a r e n t a l r a c e /
ethnicity through direct parent
interview or by chart review because
race/ethnicity has been associated with
variation in neonatal intensive care outcomes.20

Randomization

Research coordinators at each center
randomly assigned eligible infants using
an interactive voice response system.
Following eligibility screening by the
research coordinator, the system generated a unique number. The research
coordinator then telephoned the hospital blood bank staff and reported the
number. In turn, blood bank staff referred to a manual of unique numbers
generated by an independent statistician prior to study activation to determine the study intervention allocated
to the randomized patient.
The randomization schedule was
stratified by site in variable blocks of 4

and 6. Allocation occurred only after an
order to transfuse was received and only
if a supply of RBCs stored for 7 days or
less was available at the time of allocation. Randomized patients received all
transfusions during the study period according to the intervention they were
allocated. Study investigators, research coordinators, attending care
teams, and the infants’ families were
blinded to treatment allocation.
Study Outcomes

The primary outcome was a composite outcome composed of mortality and
major neonatal morbidities associated
with acute organ dysfunction or fail-

Study Interventions

Premature infants were randomly assigned to receive either RBCs stored 7
days or less (the fresh RBC group) or
current standard-issue RBCs with storage time ranging from 2 to 42 days depending on site (the standard RBC
group). For all neonatal RBC transfusions, standard-issue RBC units were divided into aliquots to increase usage and
decrease waste because of the smaller
volume of RBCs required for premature infants.
Adherence to the 7 days or less rule
was monitored by local blood bank personnel to maintain blinding, and blood
bank log statistics were collated by the
blinded statistician at the coordinating center and provided to the data and
safety monitoring board. In the standard RBC group, each aliquot was
designated for use in a single infant up
to its expiration date.21 A summary of
the standard blood bank practices is
provided in eTable 1 (available at
http://www.jama.com).
All blood products used in this trial
were collected by Canadian Blood Services or Héma-Québec and prepared by
the local hospital blood bank according to local institutional practice. Red
blood cells and other blood products
were administered in accordance with
the standard clinical practice at each
site. Transfusion triggers were not protocolized and there were no other controlled interventions in keeping with the
trial’s pragmatic design.

Table 1. Baseline Characteristics a

Characteristics
Mothers
Racial/ethnic group
White
Black
Latin American
Asian
Aboriginal
Filipino
Arab
Other/unknown
Antenatal corticosteroids
Cesarean delivery
Vaginal breech delivery
Infants
Male
Multiple birth
Born at study hospital
Antibiotics administered
Age, mean (SD), d
Gestational age, mean (SD), wk
Birth weight, mean (SD), g
5-min Apgar score, mean (SD)
CRIB score, median (IQR) b
SNAP-II day 1 score, median (IQR) c
SNAP-II day 3 score, median (IQR) c
Hemoglobin level at neonatal
intensive care unit admission,
mean (SD), g/L

Fresh
Red Blood Cell
Group
(n = 188)

123 (65.1)
24 (12.7)
1 (0.5)
8 (4.2)
20 (10.6)
4 (2.1)
1 (0.5)
8 (4.2)

138 (73.4)
17 (9.1)
4 (2.1)
6 (3.2)
10 (5.3)
0
3 (1.6)
10 (5.3)

157 (83.1)
126 (66.7)
5 (2.6)

163 (86.7)
98 (52.1)
23 (12.2)

94 (50.0)
60 (31.7)
166 (44.0)
170 (89.9)
9.9 (9.5)
26.8 (1.8)
831.8 (188.1)
6.4 (2.1)

109 (58.0)
56 (29.9)
170 (45.1)
171 (91.0)
10.0 (9.7)
26.38 (1.5)
838.3 (201.4)
6.3 (2.1)

5.0 (2.0-8.0)
14.0 (8.0-24.0)
5.0 (5.0-12.0)
149.5 (27.4)

5.0 (2.0-8.3)
14.0 (6.5-24.3)
5.0 (0.0-14.0)
147.1 (24.1)

Abbreviation: IQR, interquartile range.
a Data are expressed as No. (%) unless otherwise indicated.
b The Clinical Risk Index for Babies (CRIB) score assesses the initial (first 12 hours of life) clinical severity in preterm
infants based on birth weight, gestational age, congenital malformation, base excess, and fraction of inspired oxygen. The higher the score, the higher the risk of mortality (score range, 0 to 23).
c The Score for Neonatal Acute Physiology, version 2 (SNAP-II) is a neonatal illness severity score that evaluates 6 empirically weighted, physiology-based items during a 12-hour time frame, including lowest blood pressure, lowest temperature, PO2/FIO2 ratio, lowest serum pH, seizures, and urine output. SNAP-II has a score range of 0 (low severity)
to 115 (high severity).
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ure. In addition to death, the 4 major
morbidities comprising the composite
outcome were bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, and intraventricular hemorrhage. Red blood cell
transfusions have been associated with
the morbidities included in our composite outcome.22-24 Bronchopulmonary dysplasia was defined as oxygen
dependency for at least 28 days at 36
weeks of postmenstrual age.25 The presence of retinopathy of prematurity
(presence of extraretinal fibrovascular
tissue on ophthalmological examination) of stage 3 or greater was recorded as an outcome. A diagnosis of
necrotizing enterocolitis was based on
stage 2 or greater using Bell criteria,26
and a diagnosis of intraventricular hemorrhage was based on grade III or

greater (blood in ventricles with evidence of ventricular enlargement) using
Papile criteria.27
All relevant major morbidities comprising the primary outcomes that
were present on the day of randomization were recorded. We monitored
infants for up to 90 days of their stay
in the neonatal intensive care unit to
ascertain whether they met the threshold and definition for one of the complications included in the composite
outcome. Individual complications
had to occur after the point of randomization (the receipt of the initial
transfusion) to be included as part of
the primary outcome. We also
assessed worsening of outcomes over
the study duration. Individual elements of the composite outcome were
adjudicated independently by 2 neo-

Figure 2. Distribution of Age of Red Blood Cell Transfusion Episodes in Fresh and Standard
Groups
Fresh red blood cell group
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allocation.
As secondary outcomes, we recorded rates of individual complications comprising the composite outcome and rates of nosocomial
infections. Nosocomial infections were
categorized as clinically suspected and
positive cultures. Clinically suspected
infections implied that attending teams
observed signs suggestive of infection.
This information was derived from
medical progress notes and included administration of antibiotics. We also recorded information on the site of infection and the organism identified by
culture.
As tertiary outcomes, we examined
length of mechanical ventilation and
supplemental oxygen use, need for vasopressors, other blood products, and
invasive vascular access as well as length
of stay in the neonatal intensive care
unit. Rates of minor and major interventions were also examined. Major interventions included all major surgical procedures such as laparotomies and
thoracotomies. Minor interventions included laser therapy for retinopathy of
prematurity, tracheostomy, endoscopic procedures such as bronchoscopy, and all transcutaneous procedures such as nephrostomy and cardiac
catheterizations.
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We estimated that a total of 450 infants would be needed to detect a difference between groups, with a 2-tailed
␣ of .05 and 80% power, for a comparison of 2 independent proportions if
there was an absolute decrease of 15%
in the composite outcome measure. Our
initial estimate of sample size included an assumption of blood bank
noncompliance of 10%. The data safety
monitoring board, blinded to treatment group, reviewed 2 formal interim analyses and regular reports of our
primary composite outcome as well as
serious adverse events. With data safety
monitoring board approval, we readjusted our sample size calculation to
372 infants after the first interim analy-
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sis demonstrated an actual noncompliance rate of less than 4%.
Our primary analysis was conducted
using an intention-to-treat approach and,
therefore, included all randomized infants. Baseline characteristics of patients in the 2 treatment groups were reported using frequency distributions and
descriptive statistics including measures of central tendency and dispersion. The principal analysis of our composite measure of major neonatal
morbidities and mortality was an unadjusted 2 test comparing the proportion of events in each treatment group.
Further logistic regression analyses examined the effect of adjustment for clinically relevant covariates that were known
strong predictors of the outcome (sex,
birth weight, gestational age) or that reflected imbalances at baseline. We measured the average storage using the age
of each individual transfusion episode
as well as weighting the average age by
the volume of each transfusion episode. We conducted prespecified subgroup analyses by birth weight, gestational age, and neonatal acuity (Score for
Neonatal Acute Physiology and Clinical Risk Index for Babies scores). A perprotocol analysis of infants adherent to
their allocated treatment was also conducted to examine the robustness of our
primary estimates. All analyses were conducted using SAS version 9.2 (SAS Institute Inc). All statistical tests were
2-sided and significance was set at
P⬍.05.
RESULTS
Study Population

A total of 1752 neonates were screened
for eligibility and 377 met eligibility criteria and were randomized between
May 2006 and June 2011 (FIGURE 1).
All randomized infants completed the
trial follow-up (1 infant in each group
had consent for intervention withdrawn). Fourteen patients randomized to the fresh RBC group (n = 188)
received at least 1 transfusion of RBCs
stored for greater than 7 days. Specifically, 23 of the 151 RBC transfusions
administered to the 14 infants were of
RBCs stored greater than 7 days. Base-

line demographic and clinical characteristics were similar in both groups,
with the exception of more male infants allocated to the fresh RBC group
(TABLE 1).
The mean age of blood in the fresh
RBC group was 5.1 (SD, 2.0) days (median, 5 [interquartile range, 4.0-6.0]
days) compared with 14.6 (SD, 8.3)
days (median, 13 [interquartile range,
8.0-19.0] days) in the standard RBC
group (FIGURE 2). The mean and median volumes transfused were similar
in both groups, as were pretransfusion hemoglobin values (TABLE 2). The
mean number of donor exposures in the
fresh RBC group was 3.7 compared with
2.1 in the standard RBC group
(Table 2). Postrandomization cointer-

Major Complications and Death

A total of 199 infants (53.0%) experienced our composite primary outcome
of major complications or death. Among
infants in the fresh RBC group, 99
(52.7%) had the primary outcome compared with 100 (52.9%) in the standard
RBC group (relative risk, 1.00; 95% CI,
0.82-1.21) (TABLE 4). Ninety-seven infants representing 107 events of intraventricular hemorrhage (n=35 events),
necrotizing enterocolitis (n=37 events),
or retinopathy of prematurity (n = 35

Table 2. Transfusion Data

No. of donor exposures,
mean (SD)
Age of red blood cells, d
Mean (SD)
Median (IQR)
Weighted mean (SD) a
Weighted median (IQR)
Pretransfusion hemoglobin
level, mean (SD), g/L
Volume per transfusion
episode, mean (SD), mL
Total volume of transfusion
episodes, mL
Mean (SD)
Median (IQR)
No. of transfusion episodes
Mean (SD)
Median (IQR)
No. (%) with 1 to ⱖ10
episodes
1
2
3

Standard
Red Blood Cell
Group
(n = 189)

Fresh
Red Blood Cell
Group
(n = 188)

2.08 (1.64)

3.70 (2.70)

Mean Difference
(95% CI)
or Wilcoxon P Value
for Comparison
of Medians
1.61 (1.16 to 2.07)

14.58 (8.26)
13.00 (8.00-19.00)
13.91 (5.65)
14.00 (10.50-17.04)
95.50 (11.41)

5.10 (2.05)
5.00 (4.00-6.00)
5.08 (1.07)
5.00 (4.42-5.53)
96.20 (11.30)

−9.48 (−10.02 to −8.93)
⬍.001
−8.83 (−9.61 to −8.05)
⬍.001
0.70 (−1.61 to 3.01)

14.18 (7.84)

14.05 (6.82)

−0.14 (−0.81 to 0.53)

59.78 (42.60)
51.00 (28.00-76.00)

60.35 (40.54)
57.00 (29.00-78.50)

0.56 (−7.86 to 8.98)
.65

4.94 (3.88)
4.00 (2.00-6.00)

5.01 (4.00)
4.00 (2.00-7.00)

0.06 (−0.73 to 0.86)
.97

32 (16.93)
30 (15.87)
24 (12.70)

29 (15.43)
35 (18.62)
17 (9.04)

4
5
6
7

22 (11.64)
19 (10.05)
15 (7.94)
9 (4.76)

31 (16.50)
17 (9.04)
11 (5.85)
12 (6.38)

8
9
ⱖ10

7 (3.70)
6 (3.17)
25 (13.23)

2 (1.06)
4 (2.13)
30 (15.96)

.53 b

Abbreviation: IQR, interquartile range.
a Weighted by volume of transfusion received.
b 2 P value.
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ventions including modes of ventilation, insertion of lines and catheters,
other blood products, and major surgical and diagnostic procedures did not
differ between the 2 groups. (TABLE 3)
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Table 3. Postrandomization Cointerventions
No. (%)
Standard
Red Blood Cell
Group
(n = 189)

Fresh
Red Blood Cell
Group
(n = 188)

179 (94.7)
152 (80.4)

182 (96.8)
149 (79.3)

1.02 (0.98-1.07)
0.99 (0.89-1.09)

153 (80.9)
74 (39.2)
35 (18.5)
63 (33.3)
170 (90.0)
71 (37.6)
157 (83.1)
49 (25.9)

151 (80.3)
75 (39.9)
33 (17.6)
70 (37.2)
171 (91.0)
75 (39.9)
158 (84.0)
42 (22.3)

0.99 (0.90-1.10)
1.02 (0.79-1.31)
0.95 (0.62-1.46)
1.11 (0.85-1.46)
1.01 (0.95-1.08)
1.06 (0.82-1.36)
1.01 (0.92-1.10)
0.86 (0.60-1.23)

12 (6.4)
132 (69.8)

11 (5.9)
125 (66.5)

0.92 (0.41-2.03)
0.95 (0.83-1.09)

75 (39.7)
80 (42.3)
26 (13.8)
21 (11.1)
19 (10.1)
0
39 (20.6)
9 (4.8)

80 (42.6)
82 (43.6)
31 (16.5)
20 (10.6)
20 (10.6)
2 (1.1)
41 (21.8)
10 (5.3)

1.07 (0.84-1.36)
1.03 (0.81-1.29)
1.19 (0.74-1.93)
0.95 (0.53-1.70)
1.05 (0.58-1.91)
Not estimable
1.05 (0.71-1.55)
1.12 (0.46-2.69)

38 (20.1)
0
18 (9.5)
17 (9.0)
1 (0.5)

48 (25.5)
1 (0.5)
17 (9.0)
23 (12.2)
1 (0.5)

1.27 (0.87-1.85)
Not estimable
0.95 (0.51-1.79)
1.36 (0.75-2.46)
1.01 (0.06-15.95)

7 (3.7)
2 (1.1)

6 (3.2)
2 (1.0)

0.82 (0.30-2.52)
1.01 (0.14-7.06)

0
0

1 (0.5)
1 (0.5)

Not estimable
Not estimable

Standard Red
Blood Cell
Group
(n = 189)

Fresh Red
Blood Cell
Group
(n = 188)

Relative Risk
(95% CI)

Necrotizing enterocolitis
(Bell criteria stage ⱖ2)

15 (7.9)

15 (8.0)

1.00 (0.48-2.12)

Intraventricular hemorrhage
(Papile criteria grade ⱖ3)

11 (5.8)

18 (9.6)

1.65 (0.80-3.39)

Retinopathy of prematurity
(stage ⱖ3)

26 (13.8)

23 (12.2)

0.89 (0.53-1.50)

63 (33.3)
31 (16.4)
100 (52.9)

60 (31.9)
30 (16.0)
99 (52.7)

0.96 (0.72-1.28)
0.97 (0.61-1.54)
1.00 (0.82-1.21)

Cointerventions
Supplemental oxygen
Nasal continuous positive
airway pressure
Mechanical ventilation
High-frequency ventilation
Surfactant
Intravenous steroids
Antibiotics
Cardiovascular pressors
Peripheral intravenous line
Peripheral arterial line
Central venous line
Peripherally inserted
central catheter
Umbilical vein catheter
Umbilical artery catheter
Albumin, 5%
Albumin, 25%
Freshly frozen plasma
Pentastarch
Platelets
Immunoglobulin
Surgical procedures
Cardiothoracic surgery
Neurosurgery
Abdominal surgery
Laser eye surgery
Orthopedic/vascular
surgery
Inguinal hernia repair
Central line insertion
Diagnostic procedures
Laryngoscopy/bronchoscopy
Urologic

Relative Risk
(95% CI)

Table 4. Primary Outcomes
No. (%)

Primary Outcomes

Bronchopulmonary dysplasia
Death
Composite primary outcome:
any of above
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events) were adjudicated for presence
and severity. Analysis of the individual
components of our composite outcome
did not identify any clinically significant difference between groups except
for a statistically nonsignificant increase in rates of grade III to IV intraventricular hemorrhage in the fresh RBC
group (relative risk, 1.65; 95% CI, 0.803.39). Analysis of a composite measure
of patients experiencing any progression of intraventricular hemorrhage, necrotizing enterocolitis, or retinopathy of
prematurity yielded a relative risk of 1.04
(95% CI, 0.89-1.22) and a relative risk
of 1.01 (95% CI, 0.90-1.13) with the addition of bronchopulmonary dysplasia or
death.
Infection and Length of Stay

A total of 292 infants (77.4%) had at
least 1 clinically suspected infection,
while 248 infants had at least 1 confirmed infection. The rate of clinically
suspected infection in the fresh RBC
group was 77.7% (n = 146) vs 77.2%
(n = 146) in the standard RBC group
(relative risk, 1.01; 95% CI, 0.901.12). Rates of confirmed infections
were 67.5% (n=127) in the fresh RBC
group vs 64.0% (n=121) in the standard RBC group (relative risk, 1.06;
95% CI, 0.91-1.22) (TABLE 5). Among
confirmed cases, rates of bacterial, fungal, and viral infections were similar between the 2 groups. Major sequelae of
infections including rates of pneumonia, meningitis, and osteomyelitis were
also similar (Table 5). The median
length of neonatal intensive care unit
stay was 77 days (interquartile range,
50-104 days) in the standard RBC group
and 84 days (interquartile range, 50104 days) in the fresh RBC group (Wilcoxon P=.55).
Subgroup and Sensitivity Analyses

Prespecified subgroup analyses by birth
weight, gestational age, and sex did not
document any appreciable differences
between the fresh and standard RBC
groups (eTable 2). A per-protocol
analysis did not alter the observed effect on our primary outcome (relative
risk, 0.92; 95% CI, 0.61-1.40).
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Transfusion-Associated
Adverse Events

There were no transfusion reactions
observed in either group. One serious
adverse event potentially related to transfusion was a diagnosis of cytomegalovirus infection in an infant randomized to
the standard RBC group.
COMMENT
Among critically ill premature infants, fresh RBC transfusions compared with standard RBC transfusion
practice did not decrease or increase
rates of complications or death in our
composite measure. We did not find
any clinically meaningful or statistically significant differences in individual complications, in secondary or
tertiary outcomes, or in the prespecified subgroup analyses.
Premature infants with birth weights
less than 1250 g represent a population frequently exposed to transfusions and extremely susceptible to complications and mortality. We considered
these infants to be at high risk of complications from the adverse effects of
older RBCs. With an immature circulation, limited physiologic reserve, immature immune responses, and enhanced susceptibility to oxygen
damage, we would have expected to be
able to find evidence of benefit if fresh
RBCs had favorable biological properties.
Infants who participated in the ARIPI
trial were exposed to a significant volume and frequency of RBC transfusions. Infants were given a mean of 5
transfusions (median, 4.0), each of 14
mL. Given an estimated total blood volume of 100 mL/kg,28 this represents a
significant transfusion exposure.
Only a few small studies have compared the consequences of RBC storage times.29-31 None of these studies
evaluated clinically important consequences and none were conducted in
vulnerable premature infants. In an unblinded randomized trial, Gruenwald
et al32 compared the use of fresh reconstituted whole blood to standard blood
products in 64 newborns undergoing
cardiac surgery. The investigators docu-

mented that transfusion of fresh reconstituted whole blood decreased chest
tube blood loss, improved bleeding
scores, and shortened periods of ventilation and hospital lengths of stay.
However, the role of fresh RBCs in this
population remains unclear.
We did not find any clinically meaningful or statistically significant differences and, therefore, the many laboratory changes that occur with prolonged
RBC storage may not be as important
as once thought. Alternatively, a mean
RBC storage time of 2 weeks in the stanTable 5. Infection Outcomes

Outcome Measures
Clinically suspected infections
No. (%) with ⱖ1 infection
No. of infections
Mean (SD)
Median (IQR)
Culturally confirmed infections
No. (%) with ⱖ1 infection
No. (%) with ⱖ1 infection confirmed in
Blood
Central nervous system
Lungs
No. of infections
Mean (SD)
Median (IQR)
Bacterial infections
Any bacterial infection, No. (%)
No. (%) with ⱖ1 infection confirmed in
Blood
Central nervous system
Lungs
No. of infections
Mean (SD)
Median (IQR)
Viral infections
Any viral infection, No. (%)
No. of infections
Mean (SD)
Median (IQR)
Fungal infections
Any fungal infection, No. (%)
No. of infections
Mean (SD)
Median (IQR)
Infection sequelae, No. (%)
Pneumonia
Meningitis
Osteomyelitis

Standard
Red Blood Cell
Group
(n = 189)

Fresh
Red Blood Cell
Group
(n = 188)

Relative Risk
(95% CI)

146 (77.2)

146 (77.7)

1.01 (0.90 to 1.12)

3.7 (4.1)
2.0 (1.0-5.0)

3.9 (4.3)
3.0 (1.0-6.0)

0.23 (−0.62 to 1.08) a
.65 b

121 (64.0)

127 (67.5)

1.06 (0.91 to 1.22)

91 (48.1)
12 (6.3)
56 (29.6)

95 (50.5)
11 (5.9)
69 (36.7)

1.05 (0.86 to 1.29)
0.92 (0.42 to 2.04)
1.24 (0.93 to 1.65)

2.5 (3.0)
2.0 (0.0-4.0)

2.6 (2.9)
1.0 (0.0-4.0)

121 (64.0)

123 (65.4)

1.02 (0.88 to 1.19)

91 (48.1)
12 (6.3)
56 (29.6)

93 (49.5)
11 (5.9)
68 (36.2)

1.03 (0.84 to 1.26)
0.92 (0.42 to 2.04)
1.22 (0.91 to 1.63)

2.3 (2.8)
2.0 (0.0-4.0)

2.3 (2.6)
1.0 (0-4.0)

4 (2.1)

5 (2.7)

0.03 (0.2)
0.0 (0.0-0.0)

0.04 (0.2)
0.0 (0.0-0.0)

18 (9.5)

22 (11.7)

0.2 (0.5)
0.0 (0.0-0.0)

0.2 (0.7)
0.0 (0.0-0.0)

21 (11.1)
1 (0.5)

19 (10.1)
4 (2.1)

0

0

0.1 (−0.50 to 0.70) a
.75 b

0.0 (−0.55 to 0.55) a
.98 b
1.26 (0.34 to 4.61)
0.01 (−0.03 to 0.05) a
.73 b
1.23 (0.68 to 2.22)
0.0 (−0.12 to 0.12) a
.48 b
0.91 (0.51 to 1.64)
4.02 (0.45 to 35.65)
Not estimable

Abbreviation: IQR, interquartile range.
a Mean difference (95% CI).
b Wilcoxon P value.
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dard RBC group may not have been sufficient to detect biological effects attributed to storage or clinically
significant storage lesions occurring toward the end of the accepted RBC shelf
life. Our choice of a 7-day threshold for
fresh RBCs was based primarily on feasibility, as well as on limited laboratory evidence and precedence in other
clinical studies rather than on a strong
biological rationale. Similarly, our
choice of standard-issue RBCs as a comparator was primarily based on ethical
considerations. Choosing a specific
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range with much older RBCs would
have more deliberately evaluated the
clinical consequences of more extreme storage lesions but would have
constituted a deviation from standard
of practice and raised recruitment concerns given the lack of clinical benefit
anticipated from transfusion of exclusively older RBCs. Very premature infants receiving multiple RBC transfusions with various storage ages present
difficulties for analysis and interpretation because the biochemical, physiological, and clinical effects of interactions among the various storage times
are not known. As such, exploratory
analysis must compare patients in exclusive storage time categories (eg, infants with RBC transfusions only of
blood stored ⬍14 days vs infants with
RBC transfusions only of blood stored
ⱖ14 days). Unfortunately, there were
too few infants (n = 12) who received
RBC transfusions only of blood stored
longer than 14 days to permit meaningful analysis.
Our study population was limited to
premature, very low-birth-weight infants who required at least 1 transfusion. Results may not be generalizable
to more mature or less ill infants.
We tried to ensure that our choice
of complications included in the composite primary outcome had a plausible biological relationship to outcomes. Three suggested mechanisms
have been postulated to cause deleterious effects attributed to stored RBCs.
First, several alterations in cell membranes and in depletion of 2,3diphosphoglycerate adversely affect
oxygen transport, thereby impairing
oxygen delivery to target organs.33-36 Second, older RBCs may induce a greater
inflammatory response than fresh RBCs
because of the buildup of RBC supernatant volume.28,37,38 Finally, RBCs elicit
an immunosuppressive effect in transfusion recipients. This immunomodulatory effect in critically ill or compromised infants may result in increased
rates of nosocomial infections, in turn
leading to organ dysfunction and death.
Previous studies have focused on physiological and laboratory effects of the
1450
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dedicated donor policy rather than clinically important outcomes.39-42
In conclusion, the transfusion of
fresh RBCs did not improve clinical outcomes in high-risk, premature, very
low-birth-weight infants. We thus do
not recommend any changes to storage time practices for the provision of
RBCs to infants admitted to neonatal intensive care.
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17. Fergusson D, Hébert PC, Lee SK, et al. Clinical outcomes following institution of universal leukoreduction of blood transfusions for premature infants. JAMA.
2003;289(15):1950-1956.
18. Phelan HA, Eastman AL, Aldy K, et al. Prestorage leukoreduction abrogates the detrimental effect
of aging on packed red cells transfused after trauma:
a prospective cohort study. Am J Surg. 2012;203
(2):198-204.
19. Fergusson D, Hutton B, Hogan DL, et al. The Age
of Red Blood Cells in Premature Infants (ARIPI) randomized controlled trial: study design. Transfus Med
Rev. 2009;23(1):55-61.
20. Claydon JE, Mitton C, Sankaran K, Lee SK; Canadian Neonatal Network. Ethnic differences in risk
factors for neonatal mortality and morbidity in the neonatal intensive care unit. J Perinatol. 2007;27(7):
448-452.
21. Wang-Rodriguez J, Mannino FL, Liu E, Lane TA.
A novel strategy to limit blood donor exposure and
blood waste in multiply transfused premature infants.
Transfusion. 1996;36(1):64-70.
22. Silvers KM, Gibson AT, Russell JM, Powers HJ. Antioxidant activity, packed cell transfusions, and outcome in premature infants. Arch Dis Child Fetal Neonatal Ed. 1998;78(3):F214-F219.
23. Dani C, Reali MF, Bertini G, Martelli E, Pezzati
M, Rubaltelli FF. The role of blood transfusions and
iron intake on retinopathy of prematurity. Early Hum
Dev. 2001;62(1):57-63.
24. McGrady GA, Rettig PJ, Istre GR, Jason JM, Holman
RC, Evatt BL. An outbreak of necrotizing enterocolitis: association with transfusions of packed red
blood cells. Am J Epidemiol. 1987;126(6):11651172.
25. Jobe AH, Bancalari E. Bronchopulmonary dysplasia.
Am J Respir Crit Care Med. 2001;163(7):17231729.
26. Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal
necrotizing enterocolitis: therapeutic decisions based
upon clinical staging. Ann Surg. 1978;187(1):17.
27. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth
weights less than 1500 gm. J Pediatr. 1978;92
(4):529-534.
28. Strauss RG. Additive solutions and product age
in neonatal red blood cell transfusion. In: Herman JH,

©2012 American Medical Association. All rights reserved.

Downloaded From: https://jamanetwork.com/ on 07/04/2022

Manno CS, eds. Pediatric Transfusion Practice. Philadelphia, PA: American Association of Blood Banks;
2002:129-145.
29. Walsh TS, McArdle F, McLellan SA, et al. Does
the storage time of transfused red blood cells influence regional or global indexes of tissue oxygenation
in anemic critically ill patients? Crit Care Med. 2004;
32(2):364-371.
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